RESUMO
Continuous glucose monitoring (CGM) is safe and effective in improving glycemic control in insulin-treated patients with diabetes. However, the safety of CGM use in legally blind patients with diabetes is unknown. This is a retrospective study of seven legally blind patients with diabetes on intensive insulin therapy who were using Dexcom G6 with voice-enabled Apple's Siri feature. CGM metrics, hemoglobin A1c, and frequency of severe hypoglycemia were measured for 12 months. There was a significant reduction in A1c after 3, 6, and 12 months of Dexcom G6 with Apple Siri use (P < 0.0001). Time-in-range increased at 12 months (50.9% ± 5.5% at 3 months vs. 56.8% ± 5.5% at 12 months, P = 0.029) without increase in time spent in hypoglycemia. There was a significant reduction in severe hypoglycemia requiring medical assistance for 12 months. Voice-enabled CGM use improved glycemic control and reduced severe hypoglycemia in legally blind patients with diabetes on intensive insulin therapy.
